Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Stock

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-07 pm EDT 		5-day change 1st Jan Change
44.04 USD +0.32% Intraday chart for Bristol-Myers Squibb Company +0.23% -14.17%
May. 07 Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
May. 06 Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials (USD)

Sales 2024 * 46.02B Sales 2025 * 46.16B Capitalization 88.99B
Net income 2024 * -5.4B Net income 2025 * 10.22B EV / Sales 2024 * 2.79 x
Net Debt 2024 * 39.2B Net Debt 2025 * 31.85B EV / Sales 2025 * 2.62 x
P/E ratio 2024 *
-16.7 x
P/E ratio 2025 *
8.29 x
Employees 34,100
Yield 2024 *
5.48%
Yield 2025 *
5.76%
Free-Float 69.28%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla... Our Logo
A flurry of corporate results ahead of the Fed's rate decision Our Logo
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, Q1 2024 Earnings Call, Apr 25, 2024
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb to Participate in Upcoming Investor Conferences BU
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... BU
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases PR
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol-Myers : un BLA admis pour Opdivo sous-cutané
Malgré un fort recul lié aux soins anti-Covid, Pfizer relève ses prévisions
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Tesla, Snap, Alphabet, Microsoft, Anglo American...
Après Microsoft, Alphabet, Tesla et Apple, Amazon doit faire le job
En Direct des Marchés : Thales, Stellantis, Capgemini, Atos, VusionGroup, Orpea, Adidas, HSBC...
More news

Quotes and Performance

1 day+0.32%
1 week+0.23%
Current month+0.23%
1 month-13.82%
3 months-9.46%
6 months-15.78%
Current year-14.17%
More quotes

Highs and lows

1 week
43.33
Extreme 43.333
44.62
1 month
43.33
Extreme 43.333
51.68
Current year
43.33
Extreme 43.333
55.04
1 year
43.33
Extreme 43.333
69.10
3 years
43.33
Extreme 43.333
81.44
5 years
42.48
Extreme 42.48
81.44
10 years
42.48
Extreme 42.48
81.44
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19-11-19
Peter Arduini BRD
 Director/Board Member 59 16-03-31
Derica Rice BRD
 Director/Board Member 59 20-08-31
More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
12.97% 0 M€ +10.86% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
4.99% 2 M€ -.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
4.01% 0 M€ +5.44% -
More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date Price Change Volume
24-05-07 44.04 +0.32% 10,914,947
24-05-06 43.9 -0.20% 9,127,651
24-05-03 43.99 +0.66% 12,104,489
24-05-02 43.7 -1.15% 15,962,587
24-05-01 44.21 +0.61% 13,247,159

Delayed Quote Nyse, May 07, 2024 at 04:00 pm EDT

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-07-26 - Q2 2024 Earnings Release
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
43.9 USD
Average target price
53.19 USD
Spread / Average Target
+21.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-14.17% 88.99B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.43% 690B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.43% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.12% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.59% 323B
ABBVIE INC. Stock AbbVie Inc.
+4.89% 287B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.32% 235B
NOVARTIS AG Stock Novartis AG
+5.79% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.49% 195B
AMGEN INC. Stock Amgen Inc.
+4.26% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW